drugset
drugset / Trial / NCT03083561

A Study of LY3337641 in Japanese and Caucasian Healthy Participants

NCT03083561 ↗

Phase 1 Completed 36 enrolled Eli Lilly and Company
RandomizedParallel-groupDouble-blindBasic science

Summary

The main purpose of this study is to evaluate the safety and tolerability of LY3337641 in healthy Japanese and Caucasian participants. The study will also investigate how the body processes LY3337641 and the effect of LY3337641 on the body. The study will last up to 4 weeks for each participant. Screening may occur within 28 days prior to first dose of study drug.

Timeline

Start
2017-03-15
Primary completion
2017-05-25
Completion
2017-05-25

Drugs

EvaluationDrugModalityDoseRoute
Subject Poseltinib Unknown 5 mg Oral
Subject Poseltinib Unknown 30 mg Oral
Subject Poseltinib Unknown 80 mg Oral
Subject Poseltinib Unknown 160 mg Oral

Indications

No indication recorded.